Soleno Therapeutics(US:SLNO) Prnewswire·2026-03-11 13:21Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Soleno Therapeutics, Inc. regarding violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by May 5, 2026 [1][2] Group 1: Allegations Against Soleno Therapeutics - The complaint alleges that Soleno and its executives made false or misleading statements and failed to disclose significant safety concerns related to the Phase 3 clinical trial program for DCCR, including issues of excess fluid retention [1][2] - The administration of DCCR for treating hyperphagia in individuals with Prader-Willi syndrome (PWS) posed greater safety risks than disclosed, leading to lower commercial viability and undisclosed risks of adverse events post-launch [1][2] Group 2: Stock Price Impact - Following a critical report from Scorpion Capital on August 15, 2025, Soleno's stock price fell from over $77 per share to approximately $68 per share, a decline of nearly 12% over two trading days [1][2] - After a patient death was disclosed on September 10, 2025, the stock price dropped from more than $70 per share to about $57 per share, a decline of approximately 19% over two trading days [1][2] - On November 4, 2025, Soleno reported third-quarter financial results indicating that the earlier report disrupted the launch trajectory of DCCR, causing the stock price to decline from nearly $64 per share to approximately $47 per share, a one-day decline of about 27% [1][2]